about
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.Quantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjectsThe e-MSWS-12: improving the multiple sclerosis walking scale using item response theory.Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis.A task-oriented circuit training in multiple sclerosis: a feasibility study.Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.Activities of daily living and lesion position among multiple sclerosis patients by Bayes network.Effect of a 2-week trial of functional electrical stimulation on gait function and quality of life in people with multiple sclerosisAn exploration of impaired walking dynamics and fatigue in multiple sclerosis.Quantitative sensory and motor measures detect change overtime and correlate with walking speed in individuals with multiple sclerosis.Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridineA personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort.Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.Ecological validity of walking capacity tests in multiple sclerosis.Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).Accuracy of a custom physical activity and knee angle measurement sensor system for patients with neuromuscular disorders and gait abnormalitiesDalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.The impact of slower walking speed on activities of daily living in patients with multiple sclerosis.Integrity of the anterior visual pathway and its association with ambulatory performance in multiple sclerosis.Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.A combined exercise model for improving muscle strength, balance, walking distance, and motor agility in multiple sclerosis patients: A randomized clinical trial.Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosisOutcomes of Bariatric Surgery in Morbidly Obese Patients with Multiple Sclerosis.Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis.Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.Neurological disability and its association with walking impairment in multiple sclerosis: brief review.Changes in cognition, arm function and lower body function after slow-release Fampridine treatment.Comparing two conditions of administering the six-minute walk test in people with multiple sclerosis.Is physical exercise a multiple sclerosis disease modifying treatment?Examining the validity and sensitivity to change of the 5 and 10 sit-to-stand tests in people with multiple sclerosis.The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study.Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.Does the six-minute walk test measure walking performance or physical fitness in persons with multiple sclerosis?Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability.Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.Psychometric Properties of a Clinical Strength Assessment Protocol in People with Multiple Sclerosis.Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
P2860
Q30275324-4353BAEB-F4E9-4F44-833A-202D7C18D2B7Q30276230-DD8FFF9D-99A4-461C-90EF-B8F014F500B1Q30276511-9A9E4DE9-0F0E-4F7D-9581-9E6B1DFF934EQ30409473-4F2213F0-DC3D-44C7-9D6C-8B5E5706672FQ31028236-D91C145E-A29A-4C39-B786-E8F9CBBFD079Q33605310-66833B20-E91F-4089-8051-E6BF85D664AAQ33692810-44DAACFE-11F2-4D7F-B7B1-ABD45ECFB684Q33761057-686194FF-AEB8-4899-BFD1-DD536ABADC93Q33768737-CC8A603B-AEEA-4190-8305-93FF5C026DFEQ33937065-9AE1F690-33A1-4742-B716-84257A40203AQ34376970-7DB3FA65-F9E4-455F-872B-71BE54D04325Q34524076-480586CD-7B19-4C08-BCAF-C841CC869657Q35082770-0499C969-1A41-4B8B-95D6-45B504BF9F1BQ35114676-10AE5BF4-ECD6-478B-8B4F-131E209EB4FCQ35154139-9879CA48-F97C-4FCF-B4CD-D246F0CEA903Q35194642-57C493D2-237A-4B5F-BDB2-ED7D4D20BE9BQ35448091-E1B6E4F8-7F62-45E0-9ACE-7517D86AE6A1Q35785851-7057A23C-C857-4085-BAEC-A254BD163205Q35785888-C1C48C8F-D424-4846-8731-B0C091153215Q36358368-8029BAAA-26EA-42F0-AEBA-ED98101D1CF8Q36424217-5D27F2E0-A089-43FA-BC08-68FDE580ADE5Q36999311-935AA667-2137-4BA3-A96F-DA639C04AA92Q37261332-82989C06-6B05-49D2-A6D3-B4D5A10D43C1Q37263416-8EFBEDA2-0B2E-4176-969E-9A86E5E85C39Q37395002-28465226-FB1A-4B68-8CFE-4F560033A372Q37680960-EB4B89C2-9826-4E6A-AE35-53AF616A73F2Q37682770-9D53F06B-AB5B-4804-82A9-2D3233F4DF66Q38085336-E0388F78-908C-4A95-8421-1E5A0FD27D00Q38297020-94562F77-F202-4AF2-B32E-CDAAD6F9F2ADQ38429822-38AA4BE6-998B-4947-898F-CF282FEC53D1Q38540151-4744BB3B-B358-4B84-87FA-295AD2EA09D2Q38843064-9EDBD857-7E1B-46BC-9197-47C6A6A47094Q39043574-968341D9-FFC9-43E6-AAD0-7E7FE3939328Q39447184-9E520274-05AA-4BB8-8A1E-CBFE13D350D0Q40452137-4B620B85-40D4-4EDE-83CB-18C5B9A4AA1DQ40497519-34FAA58A-39F0-4C88-8826-F3536F4FE018Q40902038-4FE557A3-7924-4812-A35C-E70432414294Q40911930-9068909A-9F7A-4AFB-A61C-026D71873536Q42667338-2BC2A97D-E3BA-4495-9DFE-316CCE09988EQ43532290-304F2505-4E33-4A38-B7D7-EF22C49A992E
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Assessing walking disability in multiple sclerosis.
@en
type
label
Assessing walking disability in multiple sclerosis.
@en
prefLabel
Assessing walking disability in multiple sclerosis.
@en
P2860
P356
P1476
Assessing walking disability in multiple sclerosis.
@en
P2093
Carlo Pozzilli
P2860
P304
P356
10.1177/1352458512444498
P577
2012-04-24T00:00:00Z